糖尿病性神経障害　基礎から臨床のすべて

出版社： 中山書店
著者：
発行日： 2013-03-28
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784521733838
電子書籍版： 2013-03-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,700 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,700 円(税込)

購入する

商品紹介

糖尿病性神経障害は，自覚症状と病理所見の関係性において一致がみられておらず，とらえかたの難しい疾患である。現在，有効な阻止手段は血糖コントロールしかないが，放置すれば確実に進行し，生命予後にかかわる状態にまで発展するため，早期発見のアプローチが重要となる。臨床で簡易にできる診断の仕方など，臨床に即した内容を含め，基礎から臨床まで幅広く解説した書である。

目次

  • 糖尿病性神経障害　基礎から臨床のすべて

    ―目次―

    第1章　糖尿病性神経障害総論
    　糖尿病性神経障害の疫学
    　糖尿病性神経障害の病理
    　糖尿病性神経障害の診断基準
    　糖尿病性神経障害の各種スコア
    　糖尿病性神経障害の病期分類

    第2章　糖尿病性神経障害の成因
    　ポリオール代謝
    　PKC
    　酸化ストレス
    　AGE-RAGE
    　神経栄養因子
    　血流障害
    　遺伝素因

    第3章　糖尿病性神経障害の診断的検査
    　神経伝導検査
    　感覚機能検査
    　自律神経機能検査
    　病理学的検査

    第4章　糖尿病性神経障害の治療
    　代謝異常改善薬
    　糖尿病性自律神経障害の治療−病態も含めて
    　再生医療

    第5章　糖尿病性足病変とフットケア
    　糖尿病性足病変とフットケア

    第6章　糖尿病性神経障害のトピックス
    　認知障害
    　IGTニューロパチー
    　インクレチンと神経障害

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 糖尿病性神経障害総論

P.10 掲載の参考文献
1) 馬場正之. 糖尿病性神経障害. 平田幸正ほか. 最新内科学大系7 糖尿病. 中山書店 ; 1995. pp.340-51.
 
2) Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995 ; 11 : 193-225.
PubMed
3) Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997 ; 46 (Suppl 2) : S54-7.
 
4) 馬場正之, 柏村英明, 八木橋操六ほか. 慢性炎症性脱髄性神経炎 (CIDP) を併発した糖尿病の1例. 糖尿病 1992 ; 35 : 1001-6.
 
5) 馬場正之, 小川雅也, 尾崎勇ほか. CIDPの臨床. 北奥羽地区56症例の解析から. 神経内科 1999 ; 50 : 248-54.
 
6) Stewart JD, McKelvey R, Durcan L, et al. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci 1996 ; 142 : 59-64.
PubMed
7) 馬場正之, 成田祥耕, 松永宗雄ほか. 糖尿病性眼筋麻痺. 神経内科 1978 ; 7 : 319-27.
 
8) Stewart JD. Diabetic truncal neuropathy : topography of the sensory deficit. Ann Neurol 1989 ; 25 : 233-8.
PubMed
9) Baba M. Diabetic amyotrophy or proximal diabetic neuropathy an immune-mediated condition? Intern Med 2001 ; 40 : 273-4.
 
10) Ozaki I, Baba M, Matsunaga M, et al. Deleterious effect of the carpal tunnel on nerve conduction in diabetic polyneuropathy. Electromyogr Clin Neurophysiol 1988 ; 28 : 301-6.
PubMed
11) Vinik AI. Diagnosis and management of diabetic neuropathy. Clin Geriatr Med 1999 ; 15 : 293-320.
PubMed
12) 馬場正之. 糖尿病性神経障害-神経生理診断学の進歩. Diabetes Frontier 2009 ; 20 : 40-5.
Medical*Online
13) 八木橋操六. 臨床医のための糖尿病の病理. 診断と治療社 ; 2004.
 
14) 馬場正之. 糖尿病神経障害の発症と進展. 糖尿病診療マスター 2010 ; 8 : 46-50.
 
15) Baba M. Hyperesthesia : an early manifestation of diabetic polyneuropathy. Intern Med 2002 ; 41 : 1079-80.
PubMed
16) Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012 ; 18 : 926-33.
PubMed
17) Shimamura H, Baba M, Ozaki I, et al. Delayed somatosensory conduction in acute painful neuropathy of diabetes. Eur J Neurol 1996 ; 3 : 264-6.
PubMed
18) Suzuki C, Ozaki I, Tanosaki M, et al. Peripheral and central conduction abnormalities in diabetes mellitus. Neurology 2000 ; 54 : 1932-7.
PubMed
19) Baba M, Ozaki I. Electrophysiological changes in diabetic neuropathy : from subclinical alterations to disabling abnormalities. Arch Physiol Biochem 2001 ; 109 : 234-40.
PubMed
20) 國本雅也. 自律神経障害. 日本臨牀 2010 ; 68 (Suppl 9) : 586-9.
 
21) 相原一夫, 景山茂. 無自覚性低血糖. 日本臨牀 2005 ; 63 (Suppl 6) : 528-33.
 
22) 馬場正之. 有痛性糖尿病性ニューロパシー. ペインクリニック 2012 ; 33 : 849-59.
Medical*Online
23) Llewelyn JG, Thomas PK, Fonseca V, et al. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta neuropathol 1986 ; 72 : 157-63.
PubMed
24) 馬場正之. 糖尿病性神経障害. 日内会誌 2010 ; 98 : 779-86.
 
25) 馬場正之. 糖尿病有痛性神経障害の鑑別診断と治療の実際. Diabetes J 2008 ; 36 : 49-55.
 
26) 馬場正之. 電気生理で捉える糖尿病神経障害. 日本糖尿病学会編. 糖尿病学の進歩 2012. 診断と治療社 ; 2012. pp.296-300.
 
27) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
28) Adler AI, Stevens RJ, Neil A, et al. UKPDS 59 : hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002 ; 25 : 894-9.
PubMed
29) Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006 ; 29 : 340-4.
PubMed
30) Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005 ; 352 : 341-50.
PubMed
31) Baba M, Kimura K, Suda T, et al. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients. J Peripher Nerv Syst 2006 ; 11 : 176-8.
PubMed
32) Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006 ; 29 : 1538-44.
PubMed
33) Hotta N, Kawamori R, Atsumi Y, et al. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 2008 ; 25 : 818-25.
PubMed
34) Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy : a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med 2011 ; 28 : 109-16.
PubMed
35) Yasuda H, Hotta N, Nakao K, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain : results of a randomized controlled trial in Japan. J Diabetes Invest 2011 ; 2 : 132-9.
 
P.19 掲載の参考文献
1) Tesfaye S, et al. Diabetic neuropathies : update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010 ; 33 : 2285-93.
PubMed
2) Tesfaye S, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors : the EURODIAB IDDM Complications Study. Diabetologia 1996 ; 39 : 1377-84.
PubMed
3) Tesfaye S, et al ; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005 ; 352 : 341-50.
 
4) Partanen J, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995 ; 333 : 89-94.
PubMed
5) Abbott CA, et al. Explanations for the lower rates of diabetic neuropathy in Indian Asians versus Europeans. Diabetes Care 2010 ; 33 : 1325-30.
PubMed
6) Ylitalo KR, et al. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity : National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2011 ; 34 : 1642-7.
PubMed
7) Soderstrom LH, et al. Association between vitamin D and diabetic neuropathy in a nationally representative sample : results from 2001-2004 NHANES. Diabet Med 2012 ; 29 : 50-5. doi : 10. 1111/j. 1464-5491. 2011. 03379. x.
 
8) Karvestedt L, et al. Peripheral sensory neuropathy associates with micro- or macroangiopathy : results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 2009 ; 32 : 317-22.
PubMed
9) Hsu WC, et al. Somatic neuropathy is an independent predictor of all-and diabetes-related mortality in type 2 diabetic patients : a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol 2012. doi : 10.1111/j. 1468-1331. 2011. 03659. x.
 
10) Tesfaye S, et al. Painful Diabetic Peripheral Neuropathy : Consensus Recommendations on Diagnosis, Assessment and Management. Diabetes Metab Res Rev 2011. doi : 10. 1002/dmrr. 1225.
 
11) Gandhi RA, et al. Painful diabetic neuropathy is associated with greater autonomic dysfunction than painless diabetic neuropathy. Diabetes Care 2010 ; 33 : 1585-90.
PubMed
12) Vinik AI, et al. Diabetic autonomic neuropathy. Diabetes Care 2003 ; 26 : 1553-79.
PubMed
13) Spallone V, et al. Cardiovascular autonomic neuropathy in diabetes : clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011 ; 27 : 639-53.
PubMed
14) Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007 ; 115 : 387-97.
PubMed
15) 八木橋操六. 糖尿病性神経障害の簡易診断基準と病期分類の試み-糖尿病性神経障害を考える会のコンセンサスから. 末梢神経 2005 ; 16 : 79-85.
 
16) Yasuda H, et al. Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract 2007 ; 77 (Suppl 1) : S178-83.
 
17) 佐藤譲ほか. 糖尿病神経障害の発症頻度と臨床診断におけるアキレス腱反射の意義-東北地方15,000人の実態調査. 糖尿病 2007 ; 50 : 799-806.
 
18) Veves A, et al. Painful diabetic neuropathy : epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008 ; 9 : 660-74.
PubMed
19) 日本糖尿病対策推進会議. http://www.med.or.jp/tounyoubyou/index.html.
 
P.27 掲載の参考文献
1) 八木橋操六. 臨床医のための糖尿病病理. 診断と治療社 ; 2004.
 
2) Low P. 糖尿病神経障害の成因. 金澤康徳ほか監訳. ジョスリン糖尿病学 (14th Edition, Kahn CR, et al. eds). 第2版. メディカル・サイエンス・インターナショナル ; 2007. p.935.
 
3) Dyck PJ, et al. Spatial pattern of nerve fiber abnormality indicative of pathologic mechanism. Am J Pathol 1984 ; 117 : 225-38.
PubMed
4) Sumner CJ, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003 ; 60 : 108-11.
PubMed
5) Malik RA, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005 ; 48 : 578-85.
PubMed
6) Dyck PJ, et al. Impaired glycemia and diabetic polyneuropathy : the OC IG Survey. Diabetes Care 2012 ; 35 : 584-91.
PubMed
7) Yagihashi S, et al. Mechanism of diabetic neuropathy. Where are we now and where to go? J Diabetes Invest 2011 ; 2 : 18-32.
 
8) Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995 ; 11 : 193-225.
PubMed
9) Lauria G, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010 ; 17 : 903-12, e44-9.
 
P.36 掲載の参考文献
1) Boulton AJ, et al ; American Diabetes Association. Diabetic neuropathie : a statement by the American Diabetes Association. Diabetes Care 2005 ; 28 : 956-62.
 
2) Tesfaye S, et al ; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies : update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010 ; 33 : 2285-93.
 
3) 糖尿病性神経障害を考える会. 糖尿病性多発神経障害 (distal symmetric polyneuropathy) の簡易診断基準 (小改訂版). 末梢神経 2001 ; 12 : 225-7.
 
4) Dyck PJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997 ; 49 : 229-39.
PubMed
5) Feldman EL, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994 ; 17 : 1281-9.
PubMed
6) Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002 ; 25 : 2048-52.
PubMed
7) Yasuda H, et al. Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract 2007 ; 77 (Suppl 1) : S178-83.
 
8) Dyck PJ, et al. Impaired glycemia and diabetic polyneuropathy : the OC IG Survey. Diabetes Care 2012 ; 35 : 584-91.
PubMed
P.48 掲載の参考文献
1) Melzack R. The short-form McGill Pain Questionnaire. Pain 1987 ; 30 : 191-7.
PubMed
2) 小川節郎. 日本人慢性疼痛患者における神経障害性疼痛スクリーニング質問票の開発. ペインクリニック 2010 ; 31 : 1187-94.
 
3) Low PA, et al. Laboratory evaluation of autonomic failure. In : Low PA and, et al. eds. Clinical Autonomic Disorders. 3rd ed. Lippincott Williams & Wilkins ; 2008. pp.130-63.
 
4) Zilliox L, et al. Assessing autonomic dysfunction in early diabetic neuropathy : the Survey of Autonomic Symptoms. Neurology 2011 ; 76 : 1099-105.
PubMed
5) Grant IA, et al. Neuropathy tests and normative results. In : Dyck PJ, et al. eds. Diabetic Neuropathy. 2nd ed. W. B. Saunders ; 1998. pp.123-41.
 
6) Dyck PJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997 ; 49 : 229-39.
PubMed
7) Feldman EL, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994 ; 17 : 1281-9.
PubMed
8) Michigan Diabetes Research and Training Center. http://www.med.umich.edu/MDRTC/profs/survey.html#mnsi
 
9) Bril V, et al ; mTCNS Study Group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med 2009 ; 26 : 240-6.
 
10) Young MJ, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993 ; 36 : 150-4.
PubMed
P.57 掲載の参考文献
1) Boulton AJ, et al. Diabetic somatic neuropathies. Diabetes Care 2004 ; 27 : 1458-86.
PubMed
2) Dyck PJ, et al. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain 1985 ; 108 : 861-80.
PubMed
3) Dyck PJ, et al. The Rochester Diabetic Neuropathy Study : reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992 ; 42 : 1164-70.
PubMed
4) Feldman EL, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994 ; 17 : 1281-9.
PubMed
5) Dyck PJ, et al. Diabetic Polyneuropathies : Update on Research Defi nition, Diagnostic Criteria and Estimation of Severity. Diabetes Metab Res Rev 2011 ; 27 : 620-8.
 
6) Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002 ; 25 : 2048-52.
PubMed
7) Tesfaye S, et al. Diabetic neuropathies : update on defi nitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010 ; 33 : 2285-93.
 
8) Singleton JR, et al. The Utah Early Neuropathy Scale : a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst 2008 ; 13 : 218-27.
 
9) 糖尿病性神経障害を考える会. 簡易診断基準をもとにした糖尿病性多発神経障害の病期分類の公表にあたって. Peripheral Nerve 2008 ; 19 : 118-9.
 
10) 八木橋操六 (研究代表者). 糖尿病多発神経障害の臨床病期分類の確立と病期に基づいた治療ガイドラインの作成. 厚生労働省科学研究循環器疾患・糖尿病等生活習慣病対策研究事業, 平成20年度～平成22年度総合研究報告書. 2010.
 
・ Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Invest 2011 ; 2 : 33-42.
 

2章 糖尿病性神経障害の成因

P.66 掲載の参考文献
1) 三五一憲. 糖尿病性神経障害の成因論の新しい展開. Diabetes Frontier 2009 ; 20 : 46-50.
Medical*Online
2) Nakamura J, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999 ; 48 : 2090-5.
PubMed
3) Sango K, et al. High glucose-induced activation of the polyol pathway and changes of gene expression profiles in immortalized adult mouse Schwann cells IMS32. J Neurochem 2006 ; 98 : 446-58.
PubMed
4) Song Z, et al. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 2003 ; 23 : 638-47.
PubMed
5) Ho EC, et al. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 2006 ; 55 : 1946-53.
PubMed
6) 矢部千尋. AR gene, 蛋白質活性と糖尿病合併症. 堀田饒編. 糖尿病合併症治療のイノベーション-ARI (アルドース還元酵素阻害薬). 医薬ジャーナル社 ; 2002. pp. 56-65.
 
7) Hotta N, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006 ; 29 : 1538-44.
PubMed
・ Head KA. Peripheral neuropathy : pathogenic mechanisms and alternative therapies. Altern Med Rev 2006 ; 11 : 294-329.
PubMed
P.75 掲載の参考文献
1) King GL, et al. Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes 1996 ; 45 Suppl 3 : S105-8.
 
2) Uehara K, et al. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 2004 ; 53 : 3239-47.
PubMed
3) Kamiya H, et al. Polyol pathway and protein kinase C activity of rat Schwannoma cells. Diabetes Metab Res Rev 2003 ; 19 : 131-9.
 
4) Chattopadhyay M, et al. Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci 2008 ; 28 : 6652-8.
PubMed
5) Hayase F, et al. Inhibitory action of protein kinase Cbeta inhibitor on tetrodotoxinresistant Na+current in small dorsal root ganglion neurons in diabetic rats. Neurosci Lett 2007 ; 417 : 90-4.
PubMed
6) Nakamura J, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999 ; 48 : 2090-5.
PubMed
7) Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007 ; 55 : 498-510.
PubMed
8) Nishikawa T, et al. Impact of mitochondrial ROS production on diabetic vascular complications. Diabetes Res Clin Pract 2007 ; 77 Supple 1 : S41-5.
 
9) Naruse K, et al. Activation of vascular protein kinase C-β inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 2006 ; 55 : 691-8.
 
10) Inoguchi T, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes : role of vascular NAD (P) H oxidase. J Am Soc Nephrol 2003 ; 14 Suppl 3 : S227-32.
 
11) Vinik AI, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005 ; 27 : 1164-80.
PubMed
P.83 掲載の参考文献
1) Low PA. 糖尿病神経障害の成因. 金澤康徳ほか監訳. ジョスリン糖尿病学. 第2版. メディカル・サイエンス・インターナショナル ; 2007. pp. 935-49.
 
2) Schmeichel AM, et al. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003 ; 52 : 165-71.
PubMed
3) Nickander KK, et al. Effect of alpha-tocopherol deficiency on indices of oxidative stress in normal and diabetic peripheral nerve. J Neurol Sci 1994 ; 126 : 6-14.
PubMed
4) Araki E, et al. Oxidative stress : a cause and therapeutic target of diabetic complications. Journal of Diabetes Investigation 2010 ; 1 : 90-6.
PubMed
5) Nishikawa T, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000 ; 404 : 787-90.
PubMed
6) Ziegler D, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid : a meta-analysis. Diabet Med 2004 ; 21 : 114-21.
PubMed
7) Ziegler D, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997 ; 20 : 369-73.
PubMed
8) Tutuncu NB, et al. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes : a preliminary study. Diabetes Care 1998 ; 21 : 1915-8.
PubMed
9) Pergola PE, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011 ; 365 : 327-36.
PubMed
10) Gane EJ, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 2010 ; 30 : 1019-26.
 
P.89 掲載の参考文献
1) Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011 ; 46 : 217-24.
PubMed
2) Albers JW, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Tria (l DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010 ; 33 : 1090-6.
 
3) Nathan DM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 ; 353 : 2643-53.
PubMed
4) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
5) Yamagishi S, Imaizumi T. Diabetic vascular complications : pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005 ; 11 : 2279-99.
PubMed
6) Yamagishi S, et al. Receptor for advanced glycation end products (RAGE) : a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008 ; 14 : 487-95.
PubMed
7) Yamagishi S, et al. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma) -modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007 ; 7 : 463-9.
PubMed
・ Yamagishi S, et al. Agents that block advanced glycation end product (AGE) -RAGE (receptor for AGEs) -oxidative stress system : a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008 ; 17 : 983-96.
PubMed
P.95 掲載の参考文献
1) Pezet S, McMahon SB. Neurotrophins : mediators and modulators of pain. Annu Rev Neurosci 2006 ; 29 : 507-38.
PubMed
2) Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy : what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002 ; 50 : 393-413.
PubMed
3) Quattrini C, et al. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care 2008 ; 31 : 140-5.
PubMed
4) Gao WQ, et al. IGF-I deficient mice show reduced peripheral nerve conduction velocities and decreased axonal diameters and respond to exogenous IGF-I treatment. J Neurobiol 1999 ; 39 : 142-52.
PubMed
5) Grote CW, et al. Insulin receptor substrate 2 expression and involvement in neuronal insulin resistance in diabetic neuropathy. Exp Diabetes Res 2011 ; 2011 : 212571.
PubMed
6) Leist M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004 ; 305 : 239-42.
 
7) Himeno T, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011 ; 60 : 2397-406.
PubMed
8) Ropper AH, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy : a randomized, double-blinded trial. Ann Neurol 2009 ; 65 : 386-93.
PubMed
P.101 掲載の参考文献
1) 額田均. 糖尿病性神経障害の成因-血管性因子. 月刊糖尿病 2011 ; 3 : 33-40.
 
2) Baba M, et al. Prolonged ischemic conduction failure after reperfusion in diabetic nerve. Muscle Nerve 2006 ; 33 : 350-5.
PubMed
3) 額田均. 虚血性ニューロパチーと糖尿病性ニューロパチー. 神研の進歩 2003 ; 47 : 605-17.
 
4) Nukada H, et al. Pathology of acute and chronic ischemic neuropathy in atherosclerotic peripheral vascular disease. Brain 1996 ; 119 : 1449-60.
PubMed
・ 八木橋操六. 臨床医のための糖尿病病理. 診断と治療社 ; 2004.
 
P.108 掲載の参考文献
1) Hamada Y, et al. Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus. Diabet Med 1993 ; 10 : 33-8.
PubMed
2) Graham A, et al. Structure of the human aldose reductase gene. J Biol Chem 1991 ; 266 : 6872-7.
 
3) Watarai A, et al. Aldose reductase gene is associated with diabetic macroangiopathy in Japanese type 2 diabetic patients. Diabet Med 2006 ; 23 : 894-9.
PubMed
4) Sivenius K, et al. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes Care 2004 ; 27 : 2021-6.
PubMed
5) Yang L, et al. Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications. Am J Physiol Endocrinol Metab 2008 : 294 : E987-92.
PubMed
6) Yamasaki H, et al. Uncoupling protein 2 promoter polymorphism -866G/A affects peripheral nerve dysfunction in Japanese type 2 diabetic patients. Diabetes Care 2006 ; 29 : 888-94.
PubMed

3章 糖尿病性神経障害の診断的検査

P.115 掲載の参考文献
・ Kanji JN, et al. Does this patient with diabetes have large-fiber peripheral neuropathy? JAMA 2010 ; 303 : 1526-32.
PubMed
・ 松岡健平ほか編. 糖尿病性神経障害-ポリオール代謝と最近の進歩. 現代医療社 ; 2001.
 
・ Dyck PJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997 ; 49 : 229-39.
PubMed
・ 長谷川修ほか. 糖尿病性神経障害の進行を表すニューロパチー症候. 日本医事新報 2005 ; 4236 : 30-2.
Medical*Online
・ Said G, et al, Toyooka K. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy. J Neurol 2008 ; 255 : 1693-702.
PubMed
P.122 掲載の参考文献
1) Baba M, et al. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients. J Peripher Nerv Syst 2006 ; 11 : 176-8.
PubMed
2) 金春玉ほか. 健常若年成人における運動神経伝導パラメーターの左右差について. 臨床脳波 2003 ; 45 : 234-8.
Medical*Online
3) 馬場正之. 糖尿病性神経障害-神経生理診断学の進歩. Diabetes Frontier 2009 ; 20 : 40-5.
Medical*Online
4) Papanas N, Ziegler D. New diagnostic tests for diabetic distal symmetric polyneuropathy. J Diabetes Complications 2011 ; 25 : 44-51.
PubMed
5) Inui K, et al. Preferential stimulation of A delta fibers by intra-epidermal needle electrode in humans. Pain 2002 ; 96 : 247-52.
 
P.128 掲載の参考文献
1) 糖尿病性神経障害を考える会. 糖尿病性多発神経障害 (distal symmetric polyneuropathy) の簡易診断基準. 末梢神経 2003 ; 14 : 225-7.
 
2) 柴田大河, 中村二郎. 電流感覚閾値検査-ニューロメーター. Diabetes J 2008 ; 36 : 171-3.
 
3) 井関雅子. 知覚電流閾値測定装置-Neurometer (知覚神経自動検査装置 NS3000). ペインクリニック 2008 ; 29 : 1589-98.
 
4) 馬殿恵ほか. 知覚痛覚定量分析装置PainVisionRPS-2100を用いた糖尿病神経障害の評価. 糖尿病 2011 ; 54 : 493-8.
 
5) 小川吉司. 感覚機能検査. 日本臨牀 2010 ; 68 (増刊号 9) : 601-5.
 
P.135 掲載の参考文献
1) The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the defi nition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 1996 ; 6 : 125-6.
 
2) 林理之. 体位変換試験-起立試験 (いわゆるシェロング試験を含む) とヘッドアップ・ティルト試験. 日本自律神経学会編. 自律神経機能検査. 第2版. 文光堂 ; 1995. pp.4-8.
 
3) 持尾聰一郎, 岡 尚省. 老年者の糖尿病ニューロパチー. 老化と疾患 1993 ; 6 : 175-83.
 
4) 岡山直司ほか. 糖尿病と消化器. 内分泌・糖尿病科 2001 ; 13 : 550-8.
 
5) 北川靖ほか. 13C呼気試験法による胃排出能検査の標準化. J Smooth Muscle Res (Jpn Sect) 2002 ; 6 : J-129-38.
 
6) 神谷武. 胃排出機能検査. 日本自律神経学会編. 自律神経機能検査. 第3版. 文光堂 ; 2000. pp.297-300.
 
7) Ordog T, et al. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 2000 ; 49 : 1731-9.
 
P.143 掲載の参考文献
1) Smith AG, et al. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001 ; 57 : 1701-4.
PubMed
2) Malik RA. The pathology of human diabetic neuropathy. Diabetes 1997 ; 46 (Suppl 2) : S50-3.
 
3) Shun CT, et al. Skin denervation in type 2 diabetes : correlations with diabetic duration and functional impairments. Brain 2004 ; 127 : 1593-605.
PubMed
4) Kennedy WR, Wendelschafer-Crabb G. The innervation of human epidermis. J Neurol Sci 1993 ; 115 : 184-90.
PubMed
5) McCarthy BG, et al. Cutaneous innervation in sensory neuropathies : evaluation by skin biopsy. Neurology 1995 ; 45 : 1848-55.
PubMed
6) Lauria G, et al. Intraepidermal nerve fiber density at the distal leg : a worldwide normative reference study. J Peripher Nerv Syst 2010 ; 15 : 202-7.
PubMed
7) Smith AG, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006 ; 29 : 1294-9.
PubMed
8) Quattrini C, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007 ; 56 : 2148-54.
PubMed
9) Herrmann DN, et al. In vivo confocal microscopy of Meissner corpuscles as a measure of sensory neuropathy. Neurology 2007 ; 69 : 2121-7.
PubMed

4章 糖尿病性神経障害の治療

P.150 掲載の参考文献
1) 糖尿病性神経障害を考える会. 糖尿病性多発神経障害の簡易診断基準の改定について. 末梢神経 2003 ; 14 : 225-7.
 
2) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
3) Martin CL, et al ; DCCT/EDIC Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006 ; 29 : 340-4.
 
4) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
5) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
6) Hotta N, et al ; ADCT Study Group. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 2008 ; 25 : 818-25.
 
7) Gemignani F. Acute painful diabetic neuropathy induced by strict glycemic control ("insulin neuritis") : the old enigma is still unsolved. Biomed Pharmacother 2009 ; 63 : 249-50.
PubMed
8) Tesfaye S, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996 ; 39 : 329-35.
PubMed
9) Llewelyn JG, et al. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol 1986 ; 72 : 157-63.
PubMed
10) 杉本一博. 糖尿病性神経障害の成因に関する基礎的研究-インスリン作用異常の役割. 糖尿病合併症 2011 ; 25 : 14-22.
 
11) Tesfaye S, et al ; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005 ; 352 : 341-50.
 
P.155 掲載の参考文献
1) Hamada Y, Nakamura J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat Endocrinol 2004 ; 3 : 245-55.
PubMed
2) Hamada Y, et al. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon- (carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000 ; 23 : 1539-44.
PubMed
3) Nakamura J, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999 ; 48 : 2090-5.
PubMed
4) Hotta N, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006 ; 29 : 1538-44.
PubMed
5) Hotta N, et al ; SNK-860 Diabetic Neuropathy Study Group. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy : a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001 ; 24 : 1776-82.
 
6) Bril V, et al ; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009 ; 32 : 1256-60.
 
7) Ziegler D, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid : a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999 ; 22 : 1296-301.
 
8) Malik RA, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy : randomised double-blind controlled trial. Lancet 1998 ; 352 : 1978-81.
PubMed
9) Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010 ; 33 : 156?61.
 
10) Himeno T, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011 ; 60 : 2397-406.
PubMed
P.162 掲載の参考文献
1) Dworkin RH, et al. Pharmacologic management of neuropathic pain : evidence-based recommendations. Pain 2007 ; 132 : 237-51.
PubMed
2) Bril V, et al. Evidence-based guideline : Treatment of painful diabetic neuropathy : report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011 ; 76 : 1758-65.
 
3) Attal N, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain : 2010 revision. Eur J Neurol 2010 ; 17 : 1113-23.
PubMed
4) NICE (The UK's National Institute for Health and Clinical Excellence) Clinical Guideline 96. Neuropathic pain : the pharmacological management of neuropathic pain in adults in non-specialist settings. 2010.
 
5) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010. pp.103-14.
 
6) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン作成ワーキンググループ編. 神経障害性疼痛薬物療法ガイドライン. 真興交易医書出版部 ; 2011. pp.31-50.
 
7) Satoh J, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy : a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med 2011 ; 28 : 109-16.
PubMed
8) Yasuda H, et al. Superiolity of duloxetine to placebo in improving diabetic neuropathic pain : Results of a randomized controlled trial in Japan. J Diabetes Invest 2011 ; 2 : 132-9.
 
9) Hotta N, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006 ; 29 : 1538-44.
PubMed
10) 出口尚寿ほか. 糖尿病性末梢神経障害 (糖尿病多発神経障害, 局所性・多巣性糖尿病神経障害, 有痛性糖尿病神経障害). 日内会誌 2012 ; 101 : 2171-9.
 
P.167 掲載の参考文献
1) Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997 ; 46 Suppl 2 : S54-7.
 
2) 徳盛豊ほか. Diabetic amyotrophy 21例の統計的観察. 糖尿病 1979 ; 22 : 875-82.
 
3) Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies : new insights into pathophysiology and treatment. Muscle Nerve 2002 ; 25 : 477-91.
PubMed
4) 出口尚寿ほか. 糖尿病性躯幹神経障害6症例の臨床像. Diabetes Journal 2011 ; 39 : 16-20.
 
5) Said G, et al. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003 ; 126 : 376-85.
PubMed
6) 安田斎. 糖尿病性ニューロパチーの病態と治療. 臨床神経 2009 ; 49 : 149-57.
 
7) Krendel DA, et al. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995 ; 52 : 1053-61.
 
8) Zochodne DW, et al. Failure of immunotherapy to prevent, arrest or reverse diabetic lumbosacral plexopathy. Acta Neurol Scand 2003 ; 107 : 299-301.
PubMed
P.178 掲載の参考文献
1) Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care 2003 ; 26 : 1553-79.
PubMed
2) 麻生好正. 糖尿病性心血管自律神経障害の病態生理と対策. Diabetes Frontier 2009 ; 20 : 61-7.
Medical*Online
3) Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia 2012 ; 55 : 1283-90.
PubMed
4) American Diabetes Association Standards of medical care in diabetes--2011. Diabetes Care 2011 ; 34 (Suppl 1) : S11-61.
PubMed
5) 麻生好正. 糖尿病性自律神経障害の治療. 月刊糖尿病 2011 ; 3 : 69-104.
 
6) Tesfaye S, Boulton AJ, Dyck PJ, et al ; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies : update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010 ; 33 : 2285-93.
 
7) Takebayashi K, Aso Y, Sugita R, et al. Relationship between sympathetic skin response and power spectral analysis of heart rate variation in patients with type 2 diabetes. J Diabetes Complications 2004 ; 18 : 224-8.
PubMed
P.186 掲載の参考文献
1) Vincent AM, et al. Diabetic neuropathy : cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011 ; 7 : 573-83.
PubMed
2) Hotta N, et al. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 2008 ; 25 : 818-25.
PubMed
3) Nakae M, et al. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes 2006 ; 55 : 1470-7.
PubMed
4) Hasegawa T, et al. Amelioration of diabetic peripheral neuropathy by implantation of hematopoietic mononuclear cells in streptozotocin-induced diabetic rats. Exp Neurol 2006 ; 199 : 274-80.
PubMed
5) Naruse K, et al. Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in diabetic neuropathy. PLoS One 2011 ; 6 : e27458.
PubMed
6) Shibata T, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes 2008 ; 57 : 3099-107.
PubMed
7) Naruse K, et al. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 2005 ; 54 : 1823-8.
PubMed
8) Ropper AH, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy : a randomized, double-blinded trial. Ann Neurol 2009 ; 65 : 386-93.
PubMed
9) Kamiya H, et al. C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes 2006 ; 55 : 3581-7.
PubMed
10) Himeno T, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011 ; 60 : 2397-406.
PubMed
11) Okawa T, et al. Transplantation of neural crest like cells derived from induced pluripotent stem cells improves diabetic polyneuropathy in mice. Cell Transplant 2012. doi : 10. 3727/096368912X657710.
 

5章 糖尿病性足病変とフットケア

P.195 掲載の参考文献
1) Singh N, et al. Preventing foot ulcers in patients with diabetes. JAMA 2005 ; 293 : 217-28.
PubMed
2) 松岡孝. 糖尿病性神経障害と足病変. 月刊糖尿病 2011 ; 3 : 105-13.
 
3) 河野茂夫ほか. わが国における糖尿病足病変について. 国立病院機構多施設共同研究 (第5報). 糖尿病 2007 ; 50 (Suppl) : 191.
 
4) 渥美義仁. 糖尿病足病変-糖尿病内科医の行うこと. 月刊糖尿病 2009 ; 1 : 10-5.
 
5) Graziani L, et al. Vascular involvement in diabetic subjects with ischemic foot ulcer : a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg 2007 ; 33 : 453-60.
PubMed
6) Norgren L, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007 ; 45 (Suppl S) : S5-67.
 
7) Boulton AJ, et al. Comprehensive foot examination and risk assessment : a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008 ; 31 : 1679-85.
 
8) 松岡孝. 糖尿病性多発神経障害の病期分類とその問題点. PRACTICE 2006 ; 23 : 256-8.
 

6章 糖尿病性神経障害のトピックス

P.204 掲載の参考文献
1) 櫻井孝. 糖尿病と認知障害. 月刊糖尿病 2011 ; 3 : 114-23.
 
2) 櫻井孝. 認知症を伴う高齢者糖尿病の管理. 月刊糖尿病 2011 ; 3 : 103-14.
 
3) Sakurai T, et al. Differential mini-mental state examination profiles of older people with diabetes mellitus with early Alzheimer's disease. J Am Geriatr Soc 2007 ; 55 : 955-6.
PubMed
4) 中川正法ほか. 認知症の診断, 治療, ケア-専門医と開業医との連携ネットワーク. 日本内科学会雑誌 2011 ; 100 : 2214-39.
 
5) Matsuzaki T, et al. Insulin resistance is associated with the pathology of Alzheimer disease : the Hisayama study. Neurology 2010 ; 75 : 764-70.
PubMed
6) Sakurai T. Targets of the peroxisome proliferator-activated receptor γ agonist trials for the prevention of Alzheimer disease. Arch Neurol 2011 ; 68 : 542-3.
 
7) 篠原幸人ほか編. 脳卒中治療ガイドライン 2009. 協和企画 ; 2009.
 
8) Shinohara Y, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008 ; 26 : 63-70.
PubMed
9) Umegaki H, et al ; Japanese Elderly Diabetes Intervention Trial Study Group. Risk factors associated with cognitive decline in the elderly with type 2 diabetes : pooled logistic analysis of a 6-year observation in the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int 2012 ; 12 Suppl 1 : 110-6.
 
P.210 掲載の参考文献
1) Wong TY, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes : three population-based cross-sectional studies. Lancet 2008 ; 371 : 736-43.
PubMed
2) Singleton JR, et al. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001 ; 24 : 1448-53.
PubMed
3) Ziegler D, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and microangiopathy : the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008 ; 31 : 464-9.
 
4) Putz Z, et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care 2009 ; 32 : 181-3.
PubMed
5) Rajabally YA. Neuropathy and impaired glucose tolerance : an updated review of the evidence. Acta Neurol Scand 2011 ; 124 : 1-8.
PubMed
6) Tavee J, Zhou L. Small fiber neuropathy : A burning problem. Cleve Clin J Med 2009 ; 76 : 297-305.
PubMed
7) Singleton JR, et al. Microvascular complications of impaired glucose tolerance. Diabetes 2003 ; 52 : 2867-73.
PubMed
8) Smith AG, et al. Idiopathic neuropathy patients are at high risk for metabolic syndrome. J Neurol Sci 2008 ; 273 : 25-8.
PubMed
9) Smith AG, et al. Lifestyle intervention for pre-diabetec neuropathy. Diabetes Care 2006 ; 29 : 1294-9.
 
P.216 掲載の参考文献
1) Nathanson D, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure : a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012 ; 55 : 926-35.
PubMed
2) Klonoff DC, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res and Opin 2008 ; 24 : 275-86.
PubMed
3) During MJ, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003 ; 9 : 1173-9.
PubMed
4) Faivre E, et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. J Neurophysiol 2011 ; 105 : 1574-80.
PubMed
5) Himeno T, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011 ; 60 : 2397-406.
PubMed
6) Perry T, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007 ; 203 : 293-301.
 

書評

最近チェックした商品履歴

Loading...